Date: 2011-09-02
Type of information: Licensing agreement
Compound: metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program
Company: Addex Pharmaceuticals (Switzerland) Merck&Co (USA)
Therapeutic area: Neurodegenerative diseases - CNS diseases
Type agreement: licensing
Action mechanism:
Disease: Parkinson's disease
Details: Addex Pharmaceuticals will regain all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program from Merck&Co, due to further pipeline prioritization. Under the agreement, Addex will regain rights to intellectual property and know-how and can pursue the program independently. The first agreement between Addex Pharmaceuticals and Merck&Co has been concluded in 2007.
Financial terms:
Latest news:
